checkAd
    Startseite > Aktien > TG Therapeutics > Nachrichten
    TG Therapeutics Aktie
    12,584
     
    EUR
    -2,93 %
    -0,380 EUR
    Letzter Kurs 26.04.24 Tradegate
    12,464
     
    EUR
    300 STK
    Geldkurs 26.04.24
    12,724
     
    EUR
    300 STK
    Briefkurs 26.04.24
    ISIN: US88322Q1085 · WKN: A1JXW7 · SYM: NKB2 · USA

    Neueste Nachrichten

    TG Therapeutics Announces Additional Data Presentations for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
    18.04.24 · globenewswire · TG Therapeutics
    TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
    18.04.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
    15.04.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
    08.03.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
    01.03.24 · globenewswire · TG Therapeutics
    TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
    28.02.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI (ublituximab-xiiy)
    27.02.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces European Launch of BRIUMVI (ublituximab-xiiy)
    26.02.24 · globenewswire · TG Therapeutics
    TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
    23.02.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
    20.02.24 · globenewswire · TG Therapeutics
    TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
    10.01.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
    09.01.24 · globenewswire · TG Therapeutics